Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V4YW
|
|||
| Former ID |
DNCL002319
|
|||
| Drug Name |
Hepcidin mab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Anemia [ICD-11: 3A00-3A9Z; ICD-9: 280-285] | Phase 1 | [1] | |
| Company |
Eli Lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepcidin (HAMP) | Target Info | . | [2] |
| WikiPathways | Iron metabolism in placenta | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01340976) A Phase 1 Study of LY2787106 in Cancer and Anemia. U.S. National Institutes of Health. | |||
| REF 2 | The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 March; 35(3): 155-161. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.